Centers
Center for Clean Energy Innovation
Center for Data Innovation
Center for Life Sciences Innovation
Center for Korean Innovation and Competitiveness
Centre for Canadian Innovation and Competitiveness
Hamilton Center on Industrial Strategy
Schumpeter Project on Competition Policy
Issues
Clean Energy Innovation
Innovation & Competitiveness
Antitrust
Manufacturing
National Competetiveness
Productivity
Science and R&D
More...
IT & Data
AI
Data Innovation
Internet
Privacy
More...
Life Sciences & Agricultural Biotech
Agricultural Biotech
Life Sciences
Telecommunications
Broadband
Wireless
Trade & Globalization
Developing Economies
Trade
Regions
Africa
Asia-Pacific
Canada
China
Europe
Global
Latin America
United Kingdom
Publications
Reports & Briefings
Commentary
Innovation Files
In the Arena
Op-Eds & Contributed Articles
More...
Podcasts
Innovation Files
Section 230 Series
Guest Appearances
Testimonies & Filings
Books & Edited Volumes
Events
Events
Presentations
News
Press Releases
News Clips
Media Contacts
ITIF Newsletters
About
About ITIF
Staff
Board
Affiliated Experts
Supporters
Jobs
Donate
Op-Art: Drug Price Controls vs. the NIH “Cancer Moonshot” Initiative
By
Robert D. Atkinson
|
February 21, 2022
Editors’ Recommendations
September 9, 2019
The Link Between Drug Prices and Research on the Next Generation of Cures
November 22, 2021
Drug Price Controls Are Bad Policy. Congress Should Instead Double Down on Innovation to Boost Productivity in Biopharma R&D
May 20, 2021
Five Fatal Flaws in Rep. Katie Porter’s Indictment of the U.S. Drug Industry